Filings
| Filing | Date | Type | Filed with |
|---|
| Cleansing Notice | Nov 16, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - RCE | Nov 16, 2026 | Financing | ASX |
|---|
| Notification regarding unquoted securities - RCE | Nov 13, 2026 | Other filings | ASX |
|---|
| Final Director's Interest Notice - Mr McKeough | Nov 6, 2026 | Ownership change notice | ASX |
|---|
| Results of Meeting | Nov 5, 2026 | Meeting outcome | ASX |
|---|
| AGM Presentation | Nov 5, 2026 | Other filings | ASX |
|---|
| Retirement of Mr Alistair McKeough as Non-Executive Director | Nov 4, 2026 | Management or board change | ASX |
|---|
| Options Prospectus | Nov 3, 2026 | Offer document | ASX |
|---|
| Cleansing Notice | Oct 30, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - RCE | Oct 30, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| License and Commercialisation Agreement in AUS/NZ for R327G | Oct 21, 2026 | Operations update | ASX |
|---|
| License and Commercialisation Agreement in AUS/NZ for R327G | Oct 21, 2026 | Acquisition or disposal | ASX |
|---|
| Independent Review of Indonesian Phase 3 R327G Trial Data | Oct 19, 2026 | Operations update | ASX |
|---|
| Independent Review of Indonesian Phase 3 R327G Trial Data | Oct 19, 2026 | Operations update | ASX |
|---|
| Notification regarding unquoted securities - RCE | Oct 16, 2026 | Other filings | ASX |
|---|
| Amendments to Debt Facility with Avenue Capital Group | Oct 16, 2026 | Financing | ASX |
|---|
| Amendments to Debt Facility with Avenue Capital Group | Oct 16, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 6, 2026 | Meeting notice | ASX |
|---|
| Notification of cessation of securities - RCE | Oct 1, 2026 | Financing | ASX |
|---|
| Resolutions under section 249N of the Corporations Act | Sep 29, 2026 | Other filings | ASX |
|---|
| 2026 Annual General Meeting | Sep 18, 2026 | Meeting notice | ASX |
|---|
| Results of General Meeting | Sep 1, 2026 | Meeting outcome | ASX |
|---|
| General Meeting Presentation | Sep 1, 2026 | Other filings | ASX |
|---|
| Appendix 4E and FY26 Annual Report | Aug 31, 2026 | Annual report | ASX |
|---|
| Appendix 4G | Aug 31, 2026 | Other filings | ASX |
|---|
| HREC Approves Comparator Study for Pivotal Phase 3 DFI | Aug 18, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notices (x4) | Aug 6, 2026 | Ownership change notice | ASX |
|---|
| Cleansing Notice | Aug 4, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - RCE | Aug 2, 2026 | Financing | ASX |
|---|
| Completion of Share Purchase Plan and Shortfall Notice | Jul 30, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - RCE | Jul 30, 2026 | Financing | ASX |
|---|
| Notice of General Meeting/Proxy Form | Jul 30, 2026 | Proxy form | ASX |
|---|
| U.S. Government Releases US$66.9B AMR Biodefense Strategy | Jul 29, 2026 | Operations update | ASX |
|---|
| Vietnamese Patent Granted for RECCE Anti-Infectives | Jul 13, 2026 | Other filings | ASX |
|---|
| AUD $3.7M Income Tax Refund Received | Jun 30, 2026 | Results | ASX |
|---|
| Placement & SPP to raise $8 million | Jun 25, 2026 | Financing | ASX |
|---|
| HREC Approval Accelerates Global Phase 3 DFI Strategy | Jun 21, 2026 | Operations update | ASX |
|---|
| Addendum to Recce Signs Middle East Licensing Term Sheet | May 27, 2026 | Other filings | ASX |
|---|
| Recce Signs Middle East Licensing Term Sheet | May 26, 2026 | Other filings | ASX |
|---|
| Brazil Patent Granted for RECCE Anti-Infectives | Mar 24, 2026 | Other filings | ASX |
|---|
| RCE Investor Webinar Presentation Deck | Mar 19, 2026 | Other filings | ASX |
|---|
| Appendix 4D and Interim Financial Report | Feb 27, 2026 | Interim report | ASX |
|---|
| Recce Enters Second U.S. Department of Defense R&D Agreement | Feb 1, 2026 | Operations update | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 30, 2026 | Quarterly report | ASX |
|---|
| AUD $5.3m R&D Rebate Received | Jan 13, 2026 | Results | ASX |
|---|
| RCE Awarded Advanced Overseas Finding up to A$85m | Dec 15, 2025 | Financing | ASX |
|---|
| Hong Kong Patent Granted for RECCE Anti-Infectives | Nov 26, 2025 | Other filings | ASX |
|---|
| Positive Efficacy Data for Inhaled R327 in HAP/VAP Model | Nov 25, 2025 | Other filings | ASX |
|---|
| Patient Dosing Underway in Ph 3 Indonesia DFI Trial | Sep 25, 2025 | Operations update | ASX |
|---|
| Preliminary Final Report | Aug 29, 2025 | Results | ASX |
|---|
| R327G Highly Effective in Burn Wounds Model | Aug 12, 2025 | Other filings | ASX |
|---|
| Recce Signs Debt Facility with Avenue Capital Group | Jun 17, 2025 | Financing | ASX |
|---|
| Successful Placement of Entitlement Offer Shortfall | Jun 3, 2025 | Financing | ASX |
|---|
| China Patent Accepted for RECCE Anti-Infectives | May 26, 2025 | Other filings | ASX |
|---|
| Recce Enters into USA Department of Defense R&D Agreement | Apr 27, 2025 | Other filings | ASX |
|---|
| Entitlement Offer - Offer Booklet and Access Letter | Apr 22, 2025 | Offer document | ASX |
|---|
| Phase II Clinical Trial Receives Additional Approval for DFI | Apr 22, 2025 | Operations update | ASX |
|---|
| Placement and Entitlement Offer to Fund Phase III Trials | Apr 10, 2025 | Financing | ASX |
|---|
| Key Opinion Leader Presentation | Mar 2, 2025 | Operations update | ASX |
|---|
| Japan Patent Allowance for RECCE Anti-Infectives | Feb 25, 2025 | Other filings | ASX |
|---|
| Positive Phase II Data from Clinical Trial of R327 Gel | Feb 16, 2025 | Other filings | ASX |
|---|
| Trading Halt | Feb 13, 2025 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Feb 13, 2025 | Trading halt or suspension | ASX |
|---|
| Correction to Appendix 4C and Quarterly Activities Report | Feb 6, 2025 | Quarterly report | ASX |
|---|
| Patient Dosing Complete in Phase II ABSSSI Trial of R327G | Jan 20, 2025 | Other filings | ASX |
|---|
| Regulatory Approval for Registrational Phase 3 R327G Trial | Dec 8, 2024 | Operations update | ASX |
|---|
| Australia Patent Granted for RECCE Anti-Infectives | Nov 25, 2024 | Other filings | ASX |
|---|
| AUD $6.75m R&D Rebate Approved | Nov 13, 2024 | Results | ASX |
|---|
| Ethics Approval for Registrational Ph3 R327G Clinical Trial | Nov 10, 2024 | Other filings | ASX |
|---|
| AGM Presentation | Nov 5, 2024 | Meeting notice | ASX |
|---|
| Phase II ABSSSI Clinical Trial Advances to Final Stages | Nov 4, 2024 | Operations update | ASX |
|---|
| Efficacy Data & Approval to Continue Ph II ABSSSI Trial | Oct 27, 2024 | Other filings | ASX |
|---|
| Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway | Oct 8, 2024 | Other filings | ASX |
|---|
| Notice of Special General Meeting/Proxy Form | Oct 8, 2024 | Proxy form | ASX |
|---|
| Successful Completion of Share Purchase Plan | Aug 4, 2024 | Financing | ASX |
|---|
| US Department of Defense Grants US $2m for R327G | Jul 15, 2024 | Other filings | ASX |
|---|
| R327 Efficacy against WHO Priority Pathogen Acinetobacter B | Jul 8, 2024 | Other filings | ASX |
|---|
| Placement & SPP to raise $10 million - Funded to FY26 | Jul 2, 2024 | Financing | ASX |
|---|
| Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete | Jun 27, 2024 | Other filings | ASX |
|---|
| Ethics Approval Broadens to All Topical Infections | Jun 24, 2024 | Operations update | ASX |
|---|
| Further R&D Rebate Approved | Jun 18, 2024 | Financing | ASX |
|---|
| R327 added to WHO List of Antibacterial Products | Jun 18, 2024 | Other filings | ASX |
|---|
| Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial | Jun 10, 2024 | Operations update | ASX |
|---|
| Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort | May 15, 2024 | Operations update | ASX |
|---|
| MCRI Pilot Study- Positive Efficacy Data for Lung Infections | May 9, 2024 | Operations update | ASX |
|---|
| China Patent Granted for RECCE Anti-Infectives | May 6, 2024 | Other filings | ASX |
|---|
| Safety Committee Approves High Dose of 4,000mg | Apr 26, 2024 | Operations update | ASX |
|---|
| Recce Completes 5,000 R327 Doses Per Week under GMP | Apr 16, 2024 | Operations update | ASX |
|---|
| Recce Pharmaceuticals - Business Update | Apr 7, 2024 | Operations update | ASX |
|---|
| Patent Granted in Israel for RECCE Anti-Infectives | Apr 2, 2024 | Other filings | ASX |
|---|
| Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial | Mar 12, 2024 | Operations update | ASX |
|---|
| Recce Receives AUD $11.17m R&D Advance | Mar 7, 2024 | Other filings | ASX |
|---|
| Safety Committee Approves Expansion of Ph I/II DFI Trial | Feb 25, 2024 | Operations update | ASX |
|---|
| RCE Establishes Strategic Partnership in South-East Asia | Feb 5, 2024 | Operations update | ASX |
|---|
| Positive Ph I/II DFI Efficacy Data to Support Site Expansion | Jan 17, 2024 | Other filings | ASX |
|---|
| Murdoch Children's R327 Efficacy UTI in-vivo | Dec 27, 2023 | Other filings | ASX |
|---|
| RCE Awarded Further $11.17m Advanced Overseas Finding | Dec 15, 2023 | Financing | ASX |
|---|
| RCE Awarded $43.7m AusIndustry Advanced Overseas Finding | Dec 14, 2023 | Financing | ASX |
|---|
| Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo | Dec 13, 2023 | Other filings | ASX |
|---|
| Canadian Patent Granted for RECCE Anti-Infectives | Nov 22, 2023 | Other filings | ASX |
|---|
| Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial | Nov 6, 2023 | Other filings | ASX |
|---|
| Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis | Oct 23, 2023 | Other filings | ASX |
|---|
| Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial | Sep 22, 2023 | Operations update | ASX |
|---|
| Placement and Entitlement Offer | Sep 11, 2023 | Financing | ASX |
|---|
| Opening R&D Address at World AMR Congress | Sep 7, 2023 | Operations update | ASX |
|---|
| RECCE Trademark Registered - Vietnam | Sep 6, 2023 | Other filings | ASX |
|---|
| Additional Positive Patient Cases - Special Access Scheme | Aug 31, 2023 | Other filings | ASX |
|---|
| Appendix 4E and Unaudited Preliminary Report | Aug 31, 2023 | Results | ASX |
|---|
| Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial | Aug 28, 2023 | Other filings | ASX |
|---|
| Patients Dosed in R327 Diabetic Foot Infection Trial | Aug 22, 2023 | Other filings | ASX |
|---|
| Phase I/II Burn Wound Infection Trial Stage 1 Complete | Aug 21, 2023 | Other filings | ASX |
|---|
| Positive Patients Update - Special Access Scheme | Aug 7, 2023 | Other filings | ASX |
|---|
| Australian Patent Granted for RECCE Anti-Infectives | Aug 3, 2023 | Other filings | ASX |
|---|
| Bonus Canadian R&D Rebate Received | Jul 28, 2023 | Other filings | ASX |
|---|
| Scientia Completes Cohort Dosing in Phase I/II UTI Trial | Jul 28, 2023 | Other filings | ASX |
|---|
| Scientia Doses Ahead of Schedule in Phase I/II UTI Trial | Jul 24, 2023 | Other filings | ASX |
|---|
| Clarification - 5x Higher Concentration in Urine & Plasma | Jul 20, 2023 | Other filings | ASX |
|---|
| Phase I Clinical Trial Data Review Complete | Jul 19, 2023 | Other filings | ASX |
|---|
| A$801,604 R&D Rebate Advance Received | Jul 12, 2023 | Other filings | ASX |
|---|
| First Cohort Dosed in Rapid Infusion Phase I/II UTI study | Jul 10, 2023 | Other filings | ASX |
|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | Jun 29, 2023 | Other filings | ASX |
|---|
| Ethics Approval to Start Phase I/II (I.V.) Clinical Trial | Apr 17, 2023 | Other filings | ASX |
|---|
| New Family 4 Patent to be Granted for RECCE Anti-Infectives | Apr 10, 2023 | Other filings | ASX |
|---|
| Recce Receives Further A$973,144 R&D Advance | Apr 4, 2023 | Other filings | ASX |
|---|
| Corporate Presentation - WI Emergence 2023 | Mar 22, 2023 | Other filings | ASX |
|---|
| Recce Selects CMAX for Phase I/II UTI Clinical Trial | Feb 19, 2023 | Other filings | ASX |
|---|
| A$6.21m Received from R&D Rebate Payments | Jan 24, 2023 | Other filings | ASX |
|---|
| JP Morgan Healthcare Conference | Jan 10, 2023 | Other filings | ASX |
|---|
| Australian Patent to be Granted for RECCE Anti-Infectives | Jan 9, 2023 | Other filings | ASX |
|---|
| Anti-Infective Research Unit est. at Murdoch Childrens | Dec 15, 2022 | Other filings | ASX |
|---|
| Approval to Start Phase I/II Diabetic Foot Ulcer Study | Dec 8, 2022 | Other filings | ASX |
|---|
| Anti-Infective Portfolio Update and Webinar details | Oct 18, 2022 | Other filings | ASX |
|---|
| Pause in trading | Oct 17, 2022 | Trading halt or suspension | ASX |
|---|
| R327 COVID Study Update | Oct 17, 2022 | Other filings | ASX |
|---|
| Expansion and Acceleration of Clinical Programs | Sep 27, 2022 | Other filings | ASX |
|---|
| Appendix 4E | Aug 31, 2022 | Results | ASX |
|---|
| Phase I Clinical Trial of R327 I.V. - 6000mg Complete | Aug 21, 2022 | Other filings | ASX |
|---|
| Corporate Presentation - Aussie Equities Day 2022 | Jul 28, 2022 | Other filings | ASX |
|---|
| Phase I Positive Safety Data - 4000mg Complete | Jun 21, 2022 | Other filings | ASX |
|---|
| Phase I Clinical Trial R327 Advances to 4000mg | May 20, 2022 | Other filings | ASX |
|---|
| Corporate Presentation - Biotech Investor Lunch | May 16, 2022 | Other filings | ASX |
|---|
| Phase I Clinical Trial R327 Advances to High Dose Cohort | Apr 12, 2022 | Other filings | ASX |
|---|
| Anti-Viral Patent Granted in Hong Kong | Apr 11, 2022 | Other filings | ASX |
|---|
| Positive safety data from 4th Cohort -Phase I Clinical Trial | Mar 29, 2022 | Other filings | ASX |
|---|
| $3.08m R&D Rebate Received | Mar 28, 2022 | Other filings | ASX |
|---|
| Safety Committee Clears PhI R327 Dose Increase | Mar 6, 2022 | Other filings | ASX |
|---|
| S&P DJI Announces March 2022 Quarterly Rebalance | Mar 4, 2022 | Other filings | ASX |
|---|
| Positive Safety Continues in 3rd Cohort PhI Clinical Trial | Feb 20, 2022 | Other filings | ASX |
|---|
| Positive Safety Data from Third Cohort of PI Clinical Trial | Feb 7, 2022 | Other filings | ASX |
|---|
| Positive Safety Data from Second Cohort of PI Clinical Trial | Jan 18, 2022 | Other filings | ASX |
|---|
| Positive Safety Data from Phase 1 Clinical Trial | Jan 6, 2022 | Other filings | ASX |
|---|
| Patients to be Dosed in Ph 1 IV Clinical Trial of R327 | Dec 14, 2021 | Other filings | ASX |
|---|
| Update on Phase I/II Clinical Trial for Burn Wound Infection | Dec 6, 2021 | Other filings | ASX |
|---|
| Appendix 4C and Activity Report | Oct 29, 2021 | Quarterly report | ASX |
|---|
| Ethics Approval to Start Phase 1 Intravenous Clinical Trial | Oct 24, 2021 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation | Oct 12, 2021 | Trading halt or suspension | ASX |
|---|
| Court Orders Granted | Oct 11, 2021 | Legal or regulatory action | ASX |
|---|
| Suspension from Official Quotation | Oct 11, 2021 | Trading halt or suspension | ASX |
|---|
| Trading halt | Oct 8, 2021 | Trading halt or suspension | ASX |
|---|
| R327 Phase I Clinical Trial Registered on ANZCTR | Sep 30, 2021 | Other filings | ASX |
|---|
| Recce Receives Further Innovation Connections Grant | Aug 11, 2021 | Other filings | ASX |
|---|
| Anti-Viral Patent Granted in USA for RECCE Anti-Infectives | Jul 22, 2021 | Other filings | ASX |
|---|
| Anti-Viral Patent Granted in China | Jul 20, 2021 | Other filings | ASX |
|---|
| Outstanding Efficacy Against Flesh-Eating Bacteria | Jul 19, 2021 | Other filings | ASX |
|---|
| Multiple Patients Dosed in Topical Phase I/II Clinical Trial | Jul 11, 2021 | Other filings | ASX |
|---|
| Recce Clinical Pipeline Update | Jun 7, 2021 | Other filings | ASX |
|---|
| R327 Demonstrates World First Multiple Mechanisms of Action | May 27, 2021 | Other filings | ASX |
|---|
| R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO | May 19, 2021 | Other filings | ASX |
|---|
| Positive Data on RECCE 327 Against All Six ESKAPE Pathogens | May 3, 2021 | Other filings | ASX |
|---|
| RECCE 327 Registered for Topical Burns Study in Humans | Apr 15, 2021 | Other filings | ASX |
|---|
| Positive Sinusitis Patient Update - Special Access Scheme | Apr 7, 2021 | Other filings | ASX |
|---|
| Positive Sinusitis Data Against Infection | Mar 31, 2021 | Other filings | ASX |
|---|
| Anti-Viral Patent Granted in EU for RECCE Anti-Infectives | Mar 30, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces March 2021 Quarterly Rebalance | Mar 12, 2021 | Other filings | ASX |
|---|
| Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange | Mar 7, 2021 | Other filings | ASX |
|---|
| Appendix 4D and Half Yearly Report | Feb 25, 2021 | Interim report | ASX |
|---|
| Recce Applies for Dual Listing on Frankfurt Stock Exchange | Feb 23, 2021 | Other filings | ASX |
|---|
| Fiona Stanley Hospital Phase I/II Clinical Trial Agreement | Feb 15, 2021 | Other filings | ASX |
|---|
| Further Encouraging COVID Results at Doherty | Feb 11, 2021 | Other filings | ASX |
|---|
| R&D Incentive Rebate Received | Feb 3, 2021 | Other filings | ASX |
|---|
| Positive Intranasal Animal Data against SARS-CoV-2 in Study | Dec 22, 2020 | Other filings | ASX |
|---|
| RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding | Dec 7, 2020 | Other filings | ASX |
|---|
| Recce Awarded AusIndustry Advanced Overseas (R&D) Finding | Nov 25, 2020 | Other filings | ASX |
|---|
| Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives | Nov 22, 2020 | Other filings | ASX |
|---|
| Encouraging Results Against SARS-CoV-2 Virus | Nov 10, 2020 | Other filings | ASX |
|---|
| HREC Approval to Start Phase I/II Burns Wound Study | Oct 15, 2020 | Other filings | ASX |
|---|
| Murdoch Childrens Research Institute, R435 Against H.Pylori | Sep 30, 2020 | Other filings | ASX |
|---|
| Recce Completes Capital Raising of $27.95m | Sep 23, 2020 | Financing | ASX |
|---|
| R327 Phase I Study - Australias CMAX Clinical Facility | Sep 10, 2020 | Other filings | ASX |
|---|
| Positive & Concentration-Dependent Efficacy Against COVID-19 | Sep 8, 2020 | Other filings | ASX |
|---|
| Recce Pharmaceuticals Receives Innovation Connections Grant | Aug 31, 2020 | Other filings | ASX |
|---|
| Recce Pharmaceuticals Appoints James Graham as CEO | Aug 28, 2020 | Other filings | ASX |
|---|
| Positive Oral Data on New RECCE 435 Against H. pylori | Aug 4, 2020 | Other filings | ASX |
|---|
| US Researchers to Test RECCE in Expanded SARS-CoV-2 Program | Jul 16, 2020 | Other filings | ASX |
|---|
| RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program | Jul 8, 2020 | Other filings | ASX |
|---|
| Response to ASX Price and Volume Query | May 27, 2020 | Explanation request | ASX |
|---|
| Positive Data on RECCE 327 Against Neisseria gonorrhoeae | May 4, 2020 | Other filings | ASX |
|---|
| Further Positive Data on RECCE 327 Against MRSA Superbug | Apr 23, 2020 | Other filings | ASX |
|---|
This page holds 200 of 263 filings.